Narcolepsy

Narcolepsy is a chronic neurological sleep disorder caused by the brain’s inability to regulate sleep-wake cycles normally. It is characterized by excessive daytime sleepiness (EDS) and disrupted REM sleep, often leading to sudden, uncontrollable sleep attacks.

Types of Narcolepsy

  1. Narcolepsy Type 1 (NT1) – With Cataplexy
    • Defining feature: Cataplexy (sudden loss of muscle tone triggered by strong emotions like laughter or anger).
    • Low hypocretin (orexin) levels in cerebrospinal fluid (CSF).
    • Strongly associated with HLA-DQB1*06:02 genetic marker.
  2. Narcolepsy Type 2 (NT2) – Without Cataplexy
    • No cataplexy, but similar EDS and sleep disruptions.
    • Normal hypocretin levels (cause less clear).
  3. Secondary Narcolepsy (rare)
    • Caused by brain injury (e.g., tumor, trauma, multiple sclerosis).

Core Symptoms

  1. Excessive Daytime Sleepiness (EDS)
    • Overwhelming urge to sleep, even after adequate nighttime sleep.
    • “Sleep attacks” (sudden, irresistible sleep episodes).
  2. Cataplexy (NT1 only)
    • Sudden, brief muscle weakness (e.g., jaw dropping, knees buckling, or full collapse).
    • Consciousness remains intact.
  3. Sleep Paralysis
    • Temporary inability to move or speak when falling asleep or waking up.
  4. Hypnagogic/Hypnopompic Hallucinations
    • Vivid, dream-like hallucinations when falling asleep (hypnagogic) or waking up (hypnopompic).
  5. Disrupted Nighttime Sleep
    • Frequent awakenings, insomnia, or restless sleep.

Causes & Pathophysiology

  • Loss of hypocretin (orexin) neurons in the hypothalamus (key for wakefulness).
  • Autoimmune theory: Immune system mistakenly attacks hypocretin-producing cells (often post-infection, e.g., H1N1 flu).
  • Genetic predisposition: HLA-DQB1*06:02 present in ~90% of NT1 cases.

Diagnosis

  1. Clinical Evaluation
    • Epworth Sleepiness Scale (ESS) to assess daytime sleepiness.
    • Detailed history of symptoms (cataplexy, hallucinations, sleep paralysis).
  2. Polysomnography (PSG) + Multiple Sleep Latency Test (MSLT)
    • PSG (overnight sleep study): Rules out other disorders (e.g., sleep apnea).
    • MSLT (daytime nap test): Measures how quickly REM sleep occurs (≤8 mins is abnormal).
    • Required for diagnosis:
      • Mean sleep latency ≤8 mins on MSLT.
      • ≥2 sleep-onset REM periods (SOREMPs) (REM within 15 mins of falling asleep).
  3. Hypocretin-1 CSF Test (if unclear)
    • Hypocretin ≤110 pg/mL confirms NT1.

Treatment

1. Medications

For Excessive Daytime Sleepiness (EDS)

  • Stimulants
    • Modafinil/Armodafinil (first-line, low abuse risk).
    • Methylphenidate (Ritalin) or Amphetamines (Adderall) (if modafinil fails).
  • Sodium Oxybate (Xyrem/Xywav)
    • Improves nighttime sleep and reduces EDS + cataplexy.

For Cataplexy

  • Sodium Oxybate (highly effective).
  • SNRIs (venlafaxine, duloxetine) or TCAs (clomipramine).

For Sleep Paralysis & Hallucinations

  • Sodium oxybate or SSRIs/SNRIs.

2. Lifestyle & Behavioral Strategies

  • Scheduled naps (15–20 mins, 1–2x/day).
  • Strict sleep schedule (consistent bedtime/wake time).
  • Avoid caffeine/alcohol close to bedtime.
  • Exercise (improves alertness but avoid late at night).

3. Emerging Therapies

  • Hypocretin replacement (experimental).
  • Immunotherapy (for early NT1, investigational).

Complications if Untreated

  • Increased risk of motor vehicle/workplace accidents.
  • Depression, anxiety, social isolation.
  • Obesity & metabolic disorders (due to low hypocretin).

When to See a Specialist

  • Unexplained excessive sleepiness despite adequate sleep.
  • Sudden muscle weakness triggered by emotions.
  • Hallucinations or paralysis when falling asleep/waking.

Prognosis

  • Lifelong condition, but symptoms can be managed well with treatment.
  • Type 1 (with cataplexy) is usually more severe than Type 2.